1/7/2013

Cell Culture Service, a supplier of custom cells and cell-based reagents, has been acquired by Evotec for $1.5 million upfront plus as much as $1.4 million in milestone fees. Evotec said the deal would improve its ability to offer integrated drug discovery and early development services for drugmakers. "CCS' experience and technologies for large-scale cell production are a perfect fit with Evotec's screening and in vitro pharmacology activities," Evotec COO Mario Polywka said.

Related Summaries